Liquid biopsy market isforecasted to grow at high rate due to an increasesing number of detectiontechnologies, clinical studies, and high prevalence of numerous cancers.TheGlobal Liquid Biopsy Market size was valued at USD 2.4Bn in 2020 expected to reach USD 7.1 Bn by 2027, with a growing CAGR of 19.9 %during the forecast period
With the tremendous risein various genetic and molecular disorders, the number of liquid biopsy isincreasing and getting importance in health sciences. Awareness of variousgenetic and molecular disorders and their detection are expected to lubricatethe growth of liquid biopsy market.
Moreover, an increase inthe prevalence of tumors, human genetic variations, breast cancers, and geneticdisabilities and its treatments are expected to attract more customers andenhance the growth of liquid biopsy market during the forecast period. Liquidbiopsy is used in the detection of disorders to avoid the abnormalities in thegenome and detect the cancer to avoid the severity with an early detection.
Request a Sample Report- https://www.alltheresearch.com/sample-request/210
Liquid biopsy is anisolation of DNA fragments from the blood associated with the tumor cells forthe detection of genetic abnormalities. The increasing volume of tumorous cellslead to large number of phagocytes to discard the dead cells apoptotic, leadingto an increase in the cell fragments in the blood stream. These fragmentscontain the DNA which help in detecting the genetic alterations. Theapplication of liquid biopsy has grown due to monitoring of instruction insurgeries to diagnostic profiling of genome. The liquid biopsy is beneficial todetect the tumor and cancerous cells at an early stage.
The global liquid biopsymarket is broadly segmented into sample type, application, biomarker technologyend-user and region. Sample type is segregated into blood sample, urine sampleand other bio fluids (tissue fluids and saliva). Based on sample type, bloodsample segment has gained tremendous market shares in 2020 and expected to gainmore during forecast period. This is due to an increase in the rate of diagnosis,detection of various genetic disorders, and interpretation to start the earlytreatment support the growth of liquid biopsy industry in this segment.
Application is furtherbifurcated into therapy selection for metastatic breast cancer (MBS), therapyselection for other metastatic cancer and molecular health monitoring services.Based on application, therapy selection for metastatic breast cancer (MBS)segment is expected to show maximum growth in market shares for 2020, expectingmore growth during the forecast period. This is due to an increasing usage ofadvanced techniques for the diagnosis purpose. These technologies arespecialized for multiple uses such as whole genome sequencing, target genomesequencing, and many others for the prenatal testing.
The technology is dividedinto multi-gene-parallel analysis (NGS) and single gene analysis (PCRMicroarrays). Based on technology, the multi-gene-parallel analysis (NGS)segment has gained tremendous market shares in 2020 and expected to gain more duringforecast period. According to WHO-World health organization, lung cancer is themost common type of cancer leading to death, an estimate of about 1.80 milliondeaths have occurred. Thus, the high prevalence of cancer detection and itsdiagnosis are expected to drive the segment in the market.
Global Liquid BiopsyMarket by Region Outlook (Revenue, USD Million, 2021-2027)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Based on region, NorthAmerica dominated the liquid biopsy market in 2020 and is expected to maintainthe same dominance throughout the forecast period. The rising prevalence ofnumerous cancers, advanced healthcare infrastructure, increase in rapiddetection and screening technologies, increasing incidence of various tumorconditions in the population drives the growth of the market in this region.
The Global LiquidBiopsy Market Segmentation:
Global Liquid BiopsyMarket by Sample Type Outlook (Revenue, USD Million, 2021-2027)
- Blood Sample
- Urine Sample
- Other Bio Fluids (Tissue fluids and Saliva)
Global Liquid BiopsyMarket by Application Outlook (Revenue, USD Million, 2021-2027)
- Therapy Selection for Metastatic Breast Cancer (MBS)
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring Services
Global Liquid BiopsyMarket by Biomarker Outlook (Revenue, USD Million, 2021-2027)
- Circulating Tumour Cells (CTC)
- Circulating Tumour DNA (ctDNA)
- Exosomes
Global Liquid BiopsyMarket by Technology Outlook (Revenue, USD Million, 2021-2027)
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
Global Liquid BiopsyMarket by End-user Outlook (Revenue, USD Million, 2021-2027)
- Hospitals
- Diagnostic Laboratories
- Others (Research Institutes)
Key Findings:
- Based on sample type, the blood sample segment accounted for the largest share of the market in 2020 and is expected to gain more during the forecast period.
- Based on application, therapy selection for metastatic breast cancer (MBS) segment is expected to observe maximum growth in market shares (2020) and is expected to gain more witness more during the forecast period.
- Based on biomarker, the circulating tumour DNA (ctDNA) segment has gained a tremendous market share in 2020.
- Based on technology, the multi-gene-parallel analysis (NGS) segment held maximum share in 2020 and expected to maintain its dominance during the forecast period.
- Based on end-user, the diagnostic laboratories segment has gained tremendous market shares in 2020 and expected to gain more during the forecast period.
Company Profiles andCompetitive Intelligence
The key players operatingin the market are:
- Biocept, Inc.
- MDxHealth
- Myriad Genetics, Inc.
- Bio-Rad Laboratories
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Genomic Health, Inc.
- Illumina, Inc.
- Vermillion, Inc.
- Foundation Medicine, Inc.
- OncoCyte Corporation
- Veracyte, Inc, Inc.
- Guardant Health, Inc.
- NeoGenomics Laboratories, Inc.
- Personal Genome Diagnostics, Inc.
- RainDance Technologies, Inc.
- Trovagene Inc.
- Adaptive Biotechnologies.
- Cynvenio Biosystems, Inc.
Read More- https://www.alltheresearch.com/report/210/liquid-biopsy
Recent News:
- In November 2020, the Food and Drug Administration (FDA) enlarged and approved the uses for a blood test called as liquid biopsy. The test interprets the changes in the DNA of the tumor cells.
- In January 2021, the U.S FDA approved a new test for the detection of circulating DNA in the blood from the cancerous tumors. The tests interpret the severity of the disease through genetic material of the tumor cells.
